for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novavax, Inc.

NVAX.OQ

Latest Trade

4.49USD

Change

-0.14(-3.02%)

Volume

100,094

Today's Range

4.38

 - 

4.59

52 Week Range

4.01

 - 

51.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.63
Open
4.58
Volume
100,094
3M AVG Volume
18.43
Today's High
4.59
Today's Low
4.38
52 Week High
51.60
52 Week Low
4.01
Shares Out (MIL)
23.92
Market Cap (MIL)
107.41
Forward P/E
-0.83
Dividend (Yield %)
--

Latest Developments

More

Novavax Inc - EMA Concluded That Co Would Not Be Able To Use Conditional Marketing Authorization Pathway For Resvax In EU

Novavax Q2 Loss Per Share $1.69

Novavax Reaches Agreement With FDA On Late Stage Trial Design For Nanoflu

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novavax, Inc.

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Industry

Biotechnology & Drugs

Contact Info

21 Firstfield Rd

+1.240.2682000

http://www.novavax.com/

Executive Leadership

James Francis Young

Independent Chairman of the Board

Stanley C. Erck

President, Chief Executive Officer, Director

John J. Trizzino

Senior Vice President, Chief Business Officer, Chief Financial Officer and Treasurer

Gregory M. Glenn

President, Research and Development

John A. Herrmann

Senior Vice President, General Counsel, Corporate Secretary

Key Stats

2.14 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-20.600

2017

-12.600

2018

-10.000

2019(E)

-5.637
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.07
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-90.47
Return on Equity (TTM)
-74.38

Latest News

Latest News

Novavax shares plunge 65 percent as respiratory vaccine fails in late-stage trial

Novavax Inc shares crashed 65 percent on Thursday after data showed its vaccine failed to prevent RSV disease, a leading cause of respiratory infections in infants, missing the main goal of a late-stage study.

Novavax's respiratory infection vaccine fails in late-stage trial

Novavax Inc said on Thursday its vaccine to prevent RSV infection, a leading cause of a respiratory disease in infants, failed to meet the main goal of a late stage study.

BRIEF-Novavax Q1 Loss Per Share $0.14

* Q1 EARNINGS PER SHARE VIEW $-0.13 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Novavax Reports Q1 Loss Per Share $0.14

* Q1 EARNINGS PER SHARE VIEW $-0.13 -- THOMSON REUTERS I/B/E/S

BRIEF-Novavax Says Topline Efficacy Data From Prepare Phase 3 Clinical Trial Expected In Q1 Of 2019

* NOVAVAX REACHES SIGNIFICANT ENROLLMENT MILESTONE IN THE PREPARE(TM) PHASE 3 TRIAL OF ITS RSV F VACCINE

BRIEF-Novavax Prices Public Offering 30.3 Mln Common Shares At $1.65 Per Share

* SAYS PUBLIC OFFERING OF 30.3 MILLION COMMON SHARES PRICED AT $1.65PER SHARE

BRIEF-Novavax Inc Q4 Loss Per Share $0.16

* NOVAVAX PROVIDES CORPORATE UPDATE AND REPORT OF FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

BRIEF-Novavax Inc Promotes John Trizzino To CFO Role

* NOVAVAX PROMOTES JOHN J. TRIZZINO TO EXPANDED ROLE AS CHIEF BUSINESS OFFICER AND CHIEF FINANCIAL OFFICER

BRIEF-Novavax Sees Phase 2 Trial Of Nanoflu Vaccine To Begin In Q3 2018

* SAYS PHASE 2 TRIAL OF NANOFLU VACCINE EXPECTED TO BEGIN IN Q3 OF 2018

BRIEF-Novavax Inc Files For Mixed Shelf Of Up To $200 Mln

* NOVAVAX INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2zNiPwp) Further company coverage:

BRIEF-Novavax Files Prospectus Supplement Related To Issuance, Sale Of Up To $75 Mln Of Common Stock

* NOVAVAX INC FILES PROSPECTUS SUPPLEMENT RELATES TO THE ISSUANCE AND SALE OF UP TO $75 MILLION OF COMMON STOCK -SEC FILING Source text: (http://bit.ly/2Edci1c) Further company coverage:

BRIEF-Novavax Continues Phase 3 Trial Of RSV F Vaccine For Infants Via Maternal Immunization

* NOVAVAX CONTINUES PHASE 3 TRIAL OF THE RSV F VACCINE FOR INFANTS VIA MATERNAL IMMUNIZATION AND PROVIDES UPDATE ON PHASE 1/2 TRIAL OF THE NANOFLU™ VACCINE Source text for Eikon: Further company coverage:

BRIEF-Novavax Q3 loss per share $0.15

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

BRIEF-Novavax reports Q3 loss per share $0.15

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

BRIEF-Novavax Q2 loss per share $0.16

* Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Novavax reports Q2 loss per share $0.16

* Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

BRIEF-Novavax announces positive topline data from phase 2 trial and provides path forward for RSV F vaccine programs

* Novavax announces positive topline data from phase 2 older adult trial and provides path forward for RSV F vaccine programs Source text for Eikon: Further company coverage:

BRIEF-Novavax reports Q1 loss per share $0.16

* Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S

BRIEF-Novavax reports Q1 loss per share $0.16

* Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Novavax reports Q4 loss per share $0.21

* Novavax reports fourth quarter and year-end 2016 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up